CAS NO: | 151227-08-6 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | AP521 is an agonist of human5-HT1Areceptorwith anIC50of 94 nM. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | AP521 is an agonist of human 5-HT1Areceptor with IC50s of 135, 94, 254, 5530, 418, 422 and 198 nM for 5-HT1A(rat), 5-HT1A(human), 5-HT1B(rat), 5-HT1B(human), 5-HT1D(human), 5-HT5a(human) and 5-HT7(rat), respectively. AP521 also decreases the forskolin-induced cAMP accumulation from 10 nM to 10 μM[1]. | ||||||||||||||||
体内研究 (In Vivo) | AP521 significantly increases the number of shock acceptances [F(5,105)=4.46, P<0.01] at doses between 0.5 to 10 mg/kg. Oral administration of AP521 at 3 and 10 mg/kg significantly decreases freezing time [F(3,60)=2.89, P<0.05]. AP521 significantly increases the time spent on the open arms by approximately 2-fold as compare to the vehicle treated group [F(3, 36)=4.21, P<0.05 for AP521]. The anxiolytic-like effect of AP521 appears to be dose-related. AP521 significantly increases the extracellular 5-HT level of the medial prefrontal cortex (mPFC) at 10 mg/kg from 0.5 to 1 h after administration. AP521 at 3 mg/kg tends to increase the extracellular 5-HT level, however, this increase is not significant[1]. | ||||||||||||||||
分子量 | 402.89 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H19ClN2O3S | ||||||||||||||||
CAS 号 | 151227-08-6 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(62.05 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|